Opko Health, Inc. (NASDAQ: OPK)

OPKO Health, Inc. is a diversified healthcare company engaged in the development, manufacture, and commercialization of pharmaceutical products and diagnostic testing services. Its pharmaceutical business focuses on long acting therapies such as the once weekly growth hormone NGENLA and the kidney disease treatment Rayaldee, while advancing a pipeline of immuno oncology and infectious disease candidates through its subsidiary ModeX. The diagnostics business is centered on BioReference, which provides specialized laboratory testing, including the 4Kscore prostate cancer test, primarily serving patients and providers in the New York and New Jersey region as well as national clients for its specialty franchise.

The company generates revenue primarily from the sale of its pharmaceutical products and from diagnostic testing services. Pharmaceutical revenue includes royalty and profit share payments from Pfizer for NGENLA, direct sales of Rayaldee in the United States and select international markets, and income from licensing and collaboration agreements. Diagnostic revenue is derived from laboratory tests performed by BioReference, including routine and esoteric tests, with a growing contribution from the 4Kscore test following its expanded FDA label that allows use without a digital rectal examination.

The company operates through two reportable segments: pharmaceuticals and diagnostics.

• Pharmaceuticals: This segment encompasses the development and commercialization of products such as NGENLA, Rayaldee, and the pipeline assets of ModeX, including multispecific antibodies and vaccine candidates, as well as the contract manufacturing and supply operations of subsidiaries in Ireland, Spain, Mexico and Chile.

• Diagnostics: This segment consists of the clinical laboratory operations of BioReference, which provides routine and specialized testing services, maintains the national 4Kscore prostate cancer test franchise, and offers correctional healthcare testing, with a focus on the New York and New Jersey markets for core clinical and women's health testing.

OPKO holds a niche position in the pharmaceutical market where its long acting growth hormone NGENLA competes with established daily therapies from larger companies such as Novo Nordisk and Ascendis, benefiting from a once weekly dosing advantage and a global partnership with Pfizer. In diagnostics, the company differentiates itself through proprietary tests like the 4Kscore, which offers greater specificity than standard PSA assays, and faces competition from large reference laboratories such as Labcorp and Quest Diagnostics, while leveraging its CLIA certified expertise and recent focus on high margin specialty testing to improve profitability.

The company serves a broad range of customers including patients receiving its pharmaceutical therapies, healthcare providers who prescribe NGENLA and Rayaldee, and collaboration partners such as Pfizer, Vifor Fresenius Medical Care Renal Pharma, and Nicoya Macau Limited. Its diagnostic business serves physician offices, clinics, hospitals, health plans, employers, and governmental agencies, with specific customers including major health insurers and laboratory clients across the United States.